SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to mixed reactions following its earnings release and subsequent stock movement, with community members debating whether the stock is overvalued. A significant point of discussion is Michael Burry's reported short position against the company. Despite positive earnings news, the stock's high valuation and potential AI bubble concerns are driving bearish sentiment.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as investors assess the implications of Q3 earnings, which included a massive EPS beat, even as some profit forecasts fell slightly short. The community is actively discussing the company's growth in bookings and trips, particularly the impact of Uber One memberships, while also debating whether the stock is currently undervalued given its market dominance and future potential in autonomous vehicles. Short-term manipulation and broader market conditions are also being considered as factors influencing the stock's price movement.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI CRYPTO is gaining attention, particularly within communities focused on the Solana ecosystem, with some users expressing bullish sentiment while others discuss challenges. The community emphasizes a shared vision and encourages building together, fostering a sense of unity despite market conditions.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid discussions about a confirmatory trial and its potential impact on existing PMO therapies, which are facing scrutiny, while Elevidys sales remain a key focus. The community is weighing the implications for future revenue and potential FDA actions, with some speculating about a possible Roche buyout amid the uncertainty. Discussions also involve management's handling of recent data releases and their overall strategy.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin's recent price volatility has the community debating whether a longer-term correction is underway. Some traders believe institutions are strategically selling off, while others see the dip as a bear trap before a potential rally toward previous highs. Discussions also involve the influence of broader market factors, such as the Nasdaq and potential government actions, on Bitcoin's price.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending amid discussions about its potential as a leading privacy coin and a hedge against Bitcoin's volatility, as some community members suggest it could reach new all-time highs. The conversations also highlight its upcoming anniversary, possibly leading to increased attention and speculation about future developments. Simultaneously, some traders are noting its overbought conditions and anticipating a potential pullback.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as community members assess the implications of recent earnings, raised guidance, and a notable dividend yield. Discussions include whether the market is undervaluing the stock, and speculation on potential acquisitions in the competitive obesity therapeutics market with some suggesting it may be a good long-term hold. Additionally, Michael Burry's position in PFE calls is generating buzz among investors.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is trending amidst mixed sentiment, with some traders citing potential partnerships and real-world utility while others express concerns about its price action and long-term viability. Community discussions revolve around identifying key resistance levels and whether the current market cap is justified. Speculation about future developments and potential catalysts continues to fuel the conversation.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem ($VSTM) is trending as optimism grows around potential FDA approvals and encouraging clinical trial data, particularly in KRAS-mutant cancers. The community is actively discussing long-term prospects, potential buyouts, and comparisons to competitors in the oncology space. Bullish sentiment is fueled by expectations of significant valuation increases and potential for a short squeeze.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending as investors discuss the company's recent earnings report, which revealed revenue growth and cash flow positivity. Community members are debating whether the current valuation is justified amidst competition and broader market conditions. Some are optimistic about the company's future prospects, citing potential AI modeling and strategic partnerships with established brands.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue?

Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock?

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Teladoc Health Expands Clarity Platform With Workplace Safety Tool

TDOC enhances its Clarity platform with an AI-driven tool to help hospitals combat rising workplace violence incidents.

Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics

Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery.

5 Small Drug Stocks to Buy as the Industry Shows Some Recovery

Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.

Why Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates

Ironwood shares jump 9.3% as second-quarter earnings and revenues top estimates. The company maintains its 2025 outlook.

Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of +800.00% and +37.83%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?

Ironwood Pharmaceuticals shares dropped 14.6% on Wednesday after the company reported a steep revenue miss in the first quarter, attributing the shortfall to a timing shift in rebates related to its gastrointestinal drug Linzess.&nbsp;The company maintained its full-year guidance and noted progress on a strategic review and pipeline development.The stock closed at $0.79, down $0.13 on Wednesday, and remained flat in after-hours trading.Ironwood posted Q1 2025 revenue of $41.1 million, down from $74.9 million a year earlier and well below the $56.7 million consensus estimate.&nbsp;GAAP net loss widened to $37.4 million, or $0.23 per share, compared to $0.03 per share in the year-ago quarter. Non-GAAP net loss came in at $0.14 per share.The company attributed the revenue decline to a change in gross-to-net rebate reserve estimates from partner AbbVie, which impacted the phasing of&nbsp;Linzess's U.S. net sales but is not expected to affect full-year results.&nbsp;Collaboration revenue related to Linzess dropped 46% year-over-year to $38.8 million.Ironwood reaffirmed its 2025 U.S. Linzess net sales forecast of $800 million to $850 million and raised its adjusted EBITDA outlook to over $105 million.&nbsp;Prescription demand for Linzess rose 8% year-over-year in Q1, in line with expectations. The company ended the quarter with $108.5 million in cash and cash equivalents, up from $88.6 million at year-end.Management said it will focus on maximizing shareholder value, including through a planned confirmatory Phase 3 trial for apraglutide and an ongoing strategic alternatives review with Goldman Sachs.Analyst sentiment soured as Wells Fargo downgraded the company to 'Equalweight' from 'Overweight,' slashing its price target from $7 to $1, according to Koyfin.Similarly, Jefferies downgraded Ironwood to 'Hold' from 'Buy,' lowering its target from $8 to $0.70, Koyfin data said.&nbsp;On Stocktwits, sentiment was ‘bearish’ amid ‘normal’ message volume.&nbsp;Some users criticized the lack of an earnings call, with one remarking that the company simply dropped the earnings release without discussion — a departure from its decade-long tradition — and instead chose to present at a life sciences conference later in the day.&nbsp;<stembedurl>https://stocktwits.com/TeeMan123/message/613768926</stembedurl><stembedurl>https://stocktwits.com/TeeMan123/message/613804225</stembedurl>Another user noted there was little new information in the earnings release beyond what had already been disclosed on April 25,&nbsp;saying they took advantage of the post-earnings selloff to add shares at a 12% discount.<stembedurl>https://stocktwits.com/Bio_Invest101/message/613802455</stembedurl>Shares of Ironwood have fallen 81.7% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Ironwood Pharma Stock Draws Retail Investor Ire With Big Q1 Miss And No Earnings Call

The drugmaker’s first-quarter revenue of $41.1 million came in well below the consensus estimate of $56.7 million, attributed to changes in AbbVie’s gross-to-net rebate reserves. 

Equity

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$1.86
Prev Close	$1.92
Open	$1.96
Dividend Yield	0.00%
50-Day Moving Average	$1.43
Beta	0.64
Avg. Volume	1.25M
PE Ratio	-35.56

52-Week High	$5.13
52-Week Low	$0.5271
Market Capitalization	$302.13M
EPS (Annual)	$0.0055
Price to Book	-0.98
Revenue Per Employee	$1.39M
Enterprise Value/EBITDA	N/A

IRWD
Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IRWD News

IRWDIronwood Pharmaceuticals Inc - Ordinary Shares - Class A